<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Many <z:chebi fb="0" ids="35610">antineoplastic drugs</z:chebi> kill <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells by inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>This highly controlled mechanism of cell <z:hpo ids='HP_0011420'>death</z:hpo> is thought to be physiologically advantageous because apoptotic cells are removed by phagocytosis before they lose their permeability barrier, thus preventing induction of an <z:mp ids='MP_0001845'>inflammatory response</z:mp> to the dying cells </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, necrotic cells lyse and release their contents into the extracellular space, thus inducing <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In this report, we examine the effects of <z:mp ids='MP_0003674'>oxidative stress</z:mp> on chemotherapy-induced cell killing </plain></SENT>
<SENT sid="4" pm="."><plain>We find that <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> inhibits the ability of 4 different chemotherapy drugs (<z:chebi fb="0" ids="4911">VP-16</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="2" ids="27899">cisplatin</z:chebi>, and AraC) to induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> shifts the form of cell <z:hpo ids='HP_0011420'>death</z:hpo> from <z:mpath ids='MPATH_3'>apoptosis</z:mpath> to pyknosis/<z:mp ids='MP_0001651'>necrosis</z:mp>, which occurs after a significant delay compared with chemotherapy-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>It can also lower the degree of cell killing by these drugs </plain></SENT>
<SENT sid="7" pm="."><plain>These effects of <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> can be prevented by the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> agents <z:chebi fb="0" ids="31460">Desferal</z:chebi>, Tempol, and <z:chebi fb="0" ids="28262">dimethylsulfoxide</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Phagocytosis by monocyte-derived macrophages of <z:chebi fb="0" ids="4911">VP-16</z:chebi>-treated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells is also inhibited by <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Cells killed with <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> (with or without <z:chebi fb="0" ids="4911">VP-16</z:chebi>) do ultimately undergo phagocytosis, but this occurs only after they have lost their permeability barrier </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, membrane-intact apoptotic cells are recognized and phagocytosed by monocyte-derived macrophages, but membrane-intact pyknotic/necrotic cells are not </plain></SENT>
<SENT sid="11" pm="."><plain>The results suggest that chemotherapy-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and phagocytosis of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells may be enhanced by including certain <z:chebi fb="11" ids="22586">antioxidant</z:chebi> agents in the treatment protocol </plain></SENT>
</text></document>